MetaCap

Axsome Therapeutics (AXSM) vs Mirum Pharmaceuticals (MIRM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Mirum Pharmaceuticals (MIRM) has outperformed Axsome Therapeutics (AXSM) over the past year, gaining 35.5% versus a loss of 13.4%. Over five years, MIRM leads with a +616.9% price change compared with +250.4% for AXSM. Axsome Therapeutics is the larger company by market cap ($6.80 billion vs $6.28 billion), about 1.1 times the size.

On valuation, Axsome Therapeutics trades at a lower forward P/E (35.5x vs 300.4x for Mirum Pharmaceuticals). Mirum Pharmaceuticals converts more of its revenue into profit, with a net margin of -4.5% versus -28.7%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AXSM-13.44%MIRM+35.45%
+86%+34%-18%
Nov 21, 20251 yearNov 20, 2026
AXSM+261.34%MIRM+512.68%
+737%+332%-73%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AXSM versus MIRM key metrics
MetricAXSMMIRM
Share price$129.36$96.13
Market cap$6.80B$6.28B
1-day change-4.66%+0.65%
YTD return-29.17%+21.70%
1-year return-13.44%+35.45%
5-year return+250.38%+616.85%
Forward P/E35.47300.41
EPS (TTM)$-3.03$-14.47
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$638.50M$521.31M
Revenue growth (YoY)+65.55%+54.74%
Net income (latest FY)$-183.17M$-23.36M
Gross margin92.56%—
Operating margin-26.12%-4.25%
Net margin-28.69%-4.48%
52-week high$260.19$130.00
52-week low$123.00$63.23
Distance from 52-week high-50.28%-26.05%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+104.56%+64.06%
Average volume865.33K692.51K
Shares outstanding52.60M65.28M
Employees1,390470
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MIRM has outperformed AXSM by 48.9 percentage points over the past year.
  • Mirum Pharmaceuticals is more profitable, keeping -4.5 cents of every revenue dollar as net income versus -28.7 cents for Axsome Therapeutics.
  • Axsome Therapeutics grew revenue faster in its latest fiscal year (+65.55% vs +54.74%).

About Axsome Therapeutics

AXSM stock →

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura.

Health Care · Biotechnology: Pharmaceutical Preparations · 1,390 employees

About Mirum Pharmaceuticals

MIRM stock →

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 470 employees

AXSM vs MIRM FAQ

Which is bigger, Axsome Therapeutics or Mirum Pharmaceuticals?

Axsome Therapeutics (AXSM) is larger, with a market capitalization of $6.80B compared with $6.28B for Mirum Pharmaceuticals (MIRM).

Which stock has performed better over the past year, AXSM or MIRM?

MIRM returned +35.45% over the past 12 months, compared with -13.44% for AXSM (price return, excluding dividends). Past performance does not predict future results.

Are Axsome Therapeutics and Mirum Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons